Evidence map›Paper›PMID 41540924›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2026

Respiratory syncytial virus epidemiology and effectiveness of infant nirsevimab: 2024 results from the Australian Sentinel Hospital Network (FluCAN-PAEDS).

Christopher C Blyth, Ushma Wadia, Philip N Britton, Jeremy Carr, Julia E Clark, Nigel W Crawford, Te-Yu Hung, Kristine K Macartney, Helen S Marshall, Nicholas J Wood and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Christopher C BlythUniversity of Western Australia/The Kids Research Institute Australia, Perth, Australia.
Ushma WadiaUniversity of Western Australia/The Kids Research Institute Australia, Perth, Australia.
Philip N BrittonThe Children's Hospital at Westmead, Sydney, Australia.
Jeremy CarrMonash Children's Hospital, Melbourne, Australia.
Julia E ClarkQueensland Children's Hospital, Brisbane, Australia.
Nigel W CrawfordRoyal Children's Hospital, Melbourne, Australia.
Te-Yu HungRoyal Darwin Hospital, Darwin, Australia.
Kristine K MacartneyThe Children's Hospital at Westmead, Sydney, Australia.
Helen S MarshallWomen's and Children's Hospital, Adelaide, Australia.
Nicholas J WoodThe Children's Hospital at Westmead, Sydney, Australia.
Tom KotsimbosAlfred Hospital, Melbourne, Australia.
Paul M KellyCommonwealth Department of Health, Disability and Ageing, Canberra, Australia.
Allen C ChengMonash Health, Melbourne, Australia.
FluCAN-PAEDS networkAdditional members of the FluCAN-PAEDS network are listed under Collaborators and at the end of the article.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUNDRespiratory syncytial virus (RSV) is a leading cause of morbidity and mortality in young children and older adults. A long-acting anti-RSV monoclonal antibody (nirsevimab) and bivalent pre-fusion F-protein pregnancy vaccine became available to prevent RSV in young children in 2024; two RSV vaccines for adults ≥ 60 years were also available.AIMTo report 2024 RSV epidemiology in Australia, identify risk factors for severe outcomes, and use and effectiveness of RSV immunisation products.METHODSNational sentinel hospital-based RSV surveillance was established in 2024, recruiting hospitalised laboratory-confirmed RSV cases and test-negative controls from 22 sites in a national hospital network (FluCAN-PAEDS).RESULTSBetween April and December 2024, 3,998 subjects (3,415 children; 582 adults) were hospitalised with RSV. Most cases were infants < 12 months (n = 1,534; 38.4%); 1,661 (41.5%) had underlying medical conditions. Children < 6 months, First Nations children, those born preterm or with underlying medical conditions (cardiac, neurological, genetic and metabolic disease/disorders, immunosuppression) were at greatest risk of severe outcomes. Severe outcomes were more frequent in adults with malignancy, respiratory or cardiac disease. Nirsevimab effectiveness against hospitalisation in infants < 12 months in the two Australian jurisdictions with population-wide immunisation programmes was 83.1% (95% CI: 67.4-91.3). RSV vaccine use (pregnancy; adults ≥ 60 years) was limited, precluding effectiveness assessments.CONCLUSIONNational surveillance enabled timely 2024 data collection with the capability to evaluate effectiveness of immunisation products preventing RSV. Nirsevimab demonstrated comparable effectiveness to that in the northern hemisphere, informing Australia's 2025 strategy. Evaluation to assess the impact of more widespread uptake of RSV prevention products continues.

Indexed as

Antibodies, Monoclonal, HumanizedAntiviral AgentsRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesSentinel SurveillanceAdolescentAdultAgedAustraliaChildChild, PreschoolFemaleHospitalizationHumansInfantAntibodies, Monoclonal, HumanizedAntiviral AgentsRespiratory Syncytial Virus Vaccinesacute respiratory infectionAustraliaimmunisationnirsevimabrespiratory syncytial virusvaccine effectiveness

Identifiers

PMID41540924
PMCPMC12811708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.